These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35800225)

  • 21. Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.
    Vogel C; Chan A; Gril B; Kim SB; Kurebayashi J; Liu L; Lu YS; Moon H
    Jpn J Clin Oncol; 2010 Nov; 40(11):999-1013. PubMed ID: 20542996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.
    Rusnak DW; Alligood KJ; Mullin RJ; Spehar GM; Arenas-Elliott C; Martin AM; Degenhardt Y; Rudolph SK; Haws TF; Hudson-Curtis BL; Gilmer TM
    Cell Prolif; 2007 Aug; 40(4):580-94. PubMed ID: 17635524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
    Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
    Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel.
    Ashraf SQ; Nicholls AM; Wilding JL; Ntouroupi TG; Mortensen NJ; Bodmer WF
    Proc Natl Acad Sci U S A; 2012 Dec; 109(51):21046-51. PubMed ID: 23213241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.
    de Martino M; Zhuang D; Klatte T; Rieken M; Rouprêt M; Xylinas E; Clozel T; Krzywinski M; Elemento O; Shariat SF
    Cancer Biol Ther; 2014 Sep; 15(9):1239-47. PubMed ID: 24971884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
    Xia W; Liu Z; Zong R; Liu L; Zhao S; Bacus SS; Mao Y; He J; Wulfkuhle JD; Petricoin EF; Osada T; Yang XY; Hartman ZC; Clay TM; Blackwell KL; Lyerly HK; Spector NL
    Mol Cancer Ther; 2011 Aug; 10(8):1367-74. PubMed ID: 21673090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diarrhea associated with afatinib: an oral ErbB family blocker.
    Yang JC; Reguart N; Barinoff J; Köhler J; Uttenreuther-Fischer M; Stammberger U; O'Brien D; Wolf J; Cohen EE
    Expert Rev Anticancer Ther; 2013 Jun; 13(6):729-36. PubMed ID: 23506556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
    Karakashev SV; Reginato MJ
    Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
    Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
    J Clin Oncol; 2010 Sep; 28(27):4221-7. PubMed ID: 20713864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lapatinib in breast cancer.
    Bilancia D; Rosati G; Dinota A; Germano D; Romano R; Manzione L
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi26-30. PubMed ID: 17591827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.
    Aird KM; Ghanayem RB; Peplinski S; Lyerly HK; Devi GR
    Mol Cancer Ther; 2010 May; 9(5):1432-42. PubMed ID: 20406946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.
    Xia W; Bacus S; Husain I; Liu L; Zhao S; Liu Z; Moseley MA; Thompson JW; Chen FL; Koch KM; Spector NL
    Mol Cancer Ther; 2010 Feb; 9(2):292-9. PubMed ID: 20124457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
    Godinho MF; Wulfkuhle JD; Look MP; Sieuwerts AM; Sleijfer S; Foekens JA; Petricoin EF; Dorssers LC; van Agthoven T
    Br J Cancer; 2012 Sep; 107(6):947-55. PubMed ID: 22892392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening and identification of small molecule inhibitors of ErbB2-induced invasion.
    Brix DM; Rafn B; Bundgaard Clemmensen K; Andersen SH; Ambartsumian N; Jäättelä M; Kallunki T
    Mol Oncol; 2014 Dec; 8(8):1703-18. PubMed ID: 25070180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.
    Sahin O; Wang Q; Brady SW; Ellis K; Wang H; Chang CC; Zhang Q; Priya P; Zhu R; Wong ST; Landis MD; Muller WJ; Esteva FJ; Chang J; Yu D
    Cell Res; 2014 May; 24(5):542-59. PubMed ID: 24675532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
    Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
    BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.
    Mukohara T; Civiello G; Johnson BE; Janne PA
    Oncology; 2005; 68(4-6):500-10. PubMed ID: 16020981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.